{"id":4810,"date":"2024-02-20T14:08:39","date_gmt":"2024-02-20T13:08:39","guid":{"rendered":"https:\/\/immunologie-kiel.de\/?post_type=news&#038;p=4810"},"modified":"2024-03-25T14:09:42","modified_gmt":"2024-03-25T13:09:42","slug":"new-cell-therapy-for-type-1-diabetes","status":"publish","type":"news","link":"https:\/\/immunologie-kiel.de\/en\/news\/new-cell-therapy-for-type-1-diabetes\/","title":{"rendered":"New cell therapy for type 1 Diabetes"},"content":{"rendered":"\n<p>The groups from Alexander Scheffold, Institute of Immunology and Paul-Martin Holterhus, Clinic for general pediatrics, are part of a EU funded research consortium \u201cAutoantigen-specific Regulatory T cell therapy against Type 1 Diabetes (ARTiDe). The aim is to develop a novel cell based therapy to treat Type 1 Diabetes.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The groups from Alexander Scheffold, Institute of Immunology and Paul-Martin Holterhus, Clinic for general pediatrics, are part of a EU funded research consortium \u201cAutoantigen-specific Regulatory T cell therapy against Type 1 Diabetes (ARTiDe). The aim is to develop a novel cell based therapy to treat Type 1 Diabetes.<\/p>\n","protected":false},"template":"","class_list":["post-4810","news","type-news","status-publish","hentry"],"_links":{"self":[{"href":"https:\/\/immunologie-kiel.de\/en\/wp-json\/wp\/v2\/news\/4810","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/immunologie-kiel.de\/en\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/immunologie-kiel.de\/en\/wp-json\/wp\/v2\/types\/news"}],"wp:attachment":[{"href":"https:\/\/immunologie-kiel.de\/en\/wp-json\/wp\/v2\/media?parent=4810"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}